Guillain-Barré Syndrome, Myasthenia Gravis, . Dr. Abdul- Monim Batiha. Guillain-Barré Syndrome.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Approximately half of the people who develop Guillain- Barré syndrome have a mild febrile illness 2 to 3 weeks before the onset of symptoms.
The patient may first notice weakness in the lower extremities that may quickly extend to include weakness and abnormal sensations in the arms.
Sensory symptoms of paresthesias, including numbness and tingling, may occur.
Symptoms may progress for several weeks. The level of paralysis may stop at any point.
Also, nerve conduction studies record impulse transmission along the nerve fiber.
The first therapy proven to benefit patients with Guillain-Barré syndrome is plasmapheresis.
Symptoms, which vary in type and severity, may include asymmetrical ptosis (a drooping of one or both eyelids), diplopia (double vision) due to weakness of the muscles that control eye movements, an unstable or waddling gait, weakness in arms, hands, fingers, legs, and neck, a change in facial expression, dysphagia (difficulty in swallowing), shortness of breath and dysarthria (impaired speech).
In myasthenic crisis a paralysis of the respiratory muscles occurs, necessitating assisted ventilation to sustain life. In patients whose respiratory muscles are already weak, crises may be triggered by infection, fever, an adverse reaction to medication, or emotional stress. Since the heart muscle is only regulated by the autonomic nervous system, it is generally unaffected by MG.
long-term immunosuppression with corticosteroids, azathioprine (Imuran), cyclophosphamide (Cytoxan), or cyclosporine;